<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25751257</article-id><article-id pub-id-type="pmc">4353622</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0118659</article-id><article-id pub-id-type="publisher-id">PONE-D-14-36085</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Cytoplasmic Expression of Pontin in Renal Cell Carcinoma Correlates with Tumor Invasion, Metastasis and Patients&#x02019; Survival</article-title><alt-title alt-title-type="running-head">The Role of Pontin in Renal Cell Carcinomas</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Juchao</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Lei</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Yueqing</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Wenhua</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Dawei</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zang</surname><given-names>Yuanwei</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kong</surname><given-names>Feng</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Zhonghua</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Urology, Qilu Hospital, Shandong University, Jinan, Shandong Province, China</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Institute of Basic Medical Science and Key Laboratory of Cardiovascular Proteomics of Shandong Province, Qilu Hospital, Shandong University, Jinan, Shandong Province, China</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Central Laboratory, Shandong University Second Hospital, Shandong University, Jinan, Shandong Province, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Sun</surname><given-names>Lu-Zhe</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Texas Health Science Center, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: XZ ZX. Performed the experiments: XZ JR DL YZ. Analyzed the data: XZ ZX LY YT WZ. Contributed reagents/materials/analysis tools: XZ ZX FK. Wrote the paper: XZ ZX.</p></fn><corresp id="cor001">* E-mail: <email>rjchao1983@163.com</email> (JR); <email>xuzhonghuamd@aliyun.com</email> (ZX)</corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>3</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>3</issue><elocation-id>e0118659</elocation-id><history><date date-type="received"><day>11</day><month>8</month><year>2014</year></date><date date-type="accepted"><day>8</day><month>1</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Zhang et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0118659.pdf"/><abstract><p>Renal cell carcinoma (RCC) is the most lethal of all genitourinary malignancies. Distant metastasis represents the major cause of death in patients with RCC. Recent studies have implicated the AAA+ ATPase pontin in many cellular activities that are highly relevant to carcinogenesis. In this study, we demonstrate for the first time that pontin was up-regulated in RCC, and plays a previously unknown pro-invasive role in the metastatic progression of RCC through epithelial-to-mesenchymal transition (EMT) pathway. 28 pairs of freshly frozen clear cell RCC samples and the matched normal renal tissues analyzed by quantitative RT-PCR and western blotting demonstrated that pontin was up-regulated in clear cell RCC tissues than in normal renal tissues. In addition, immunohistochemistry was used to evaluate subcellular pontin expression in 95 RCC patients, and found that overexpression of pontin in cytoplasm positively correlated with the metastatic features, predicting unfavorable outcomes of RCC patients. Furthermore, <italic>in vitro</italic> experiments show pontin was predominantly expressed in cytoplasm of RCC cell lines, and a significant suppression of cell migration and invasion in pontin siRNA treated RCC cell lines was observed. Mechanistic studies show that pontin depletion up-regulated the E-cadherin protein and down-regulated vimentin protein, and decreased nuclear &#x003b2;-catenin expression, suggesting the involvement of EMT in pontin induced metastatic progression. Together, our data suggest pontin as a potential prognostic biomarker in RCC, and provide new promising therapeutic targets for clinical intervention of kidney cancers.</p></abstract><funding-group><funding-statement>This project was supported by the National Natural Science Foundation of China (No. 81372335), National Science Foundation of Shandong (No. ZR2010HM103) and China Postdoctoral Science Foundation (No. 2014M551915). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="15"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Renal cell carcinoma (RCC) is the most common malignances of adult kidneys. Due to the asymptomatic nature of early stage RCC, more than one third of the patients present with locally advanced or metastatic disease at the time of diagnosis. And the prognosis of the patients with metastatic RCC is extremely poor with a 5-year survival rate less than 9% [<xref rid="pone.0118659.ref001" ref-type="bibr">1</xref>]. Understanding the molecular mechanisms of RCC metastatic progression will help identify novel potential molecular targets for the development of effective therapy. However, the study on searching for molecular targets in RCC that has clinical significance remains substantially limited.</p><p>Pontin and reptin belong to the AAA+ (ATPase associated with diverse cellular activities) superfamily, which are highly evolutionarily conserved. Pontin and reptin are usually co-expressed [<xref rid="pone.0118659.ref002" ref-type="bibr">2</xref>]. Both of them are found in several multi-protein complexes, where they are thought to participate notably in chromatin remodeling [<xref rid="pone.0118659.ref003" ref-type="bibr">3</xref>], transcriptional regulation [<xref rid="pone.0118659.ref004" ref-type="bibr">4</xref>], DNA damage repair [<xref rid="pone.0118659.ref005" ref-type="bibr">5</xref>], and small nucleolar RNA biogenesis [<xref rid="pone.0118659.ref006" ref-type="bibr">6</xref>], but they can also function independently from each other. Notably, they interact with several oncogenic transcriptional factors, such as <italic>&#x003b2;</italic>-catenin and c-myc, and modulate their activities [<xref rid="pone.0118659.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0118659.ref009" ref-type="bibr">9</xref>]. Functional studies indicated both proteins participating in tumorigenic activities. Silencing of pontin <italic>in vitro</italic> led to tumor growth arrest [<xref rid="pone.0118659.ref010" ref-type="bibr">10</xref>], and silencing of reptin in vivo significantly reduced tumor progression within xenografts in mice [<xref rid="pone.0118659.ref011" ref-type="bibr">11</xref>]. These features suggest their potential in being good targets for cancer therapy. Aberrant expression of pontin and/or reptin has been reported in malignancies of liver [<xref rid="pone.0118659.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0118659.ref012" ref-type="bibr">12</xref>], colon [<xref rid="pone.0118659.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0118659.ref014" ref-type="bibr">14</xref>], breast [<xref rid="pone.0118659.ref015" ref-type="bibr">15</xref>], among others. However, the expression and biological function of pontin in RCC has so far not been elucidated.</p><p>In our previous study, we firstly reported that reptin is overexpressed in RCC, and cytoplasmic expression of reptin predicts an unfavorable outcome for RCC patients [<xref rid="pone.0118659.ref016" ref-type="bibr">16</xref>]. Now we presume that pontin, as a homology partner of reptin, may also play an important role in RCC metastasis. The present study was performed to examine the postulated oncogenic role of pontin in RCC. In this respect, we examined pontin expression in RCC surgical samples, and explored the potential effects of pontin on RCC metastatic progression and patients&#x02019; survival. In addition, we applied siRNA to knockdown pontin in RCC cell lines to examine its biological functions and the possible molecular mechanisms.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Ethics statement</title><p>The study was approved by Ethics Boards of Qilu Hospital, Shandong University. All tissue sample acquisition was carried out according to the institutional guidelines, and all subjects signed written informed consent.</p></sec><sec id="sec004"><title>Clinical RCC specimens and RCC cell lines</title><p>For immunohistochemical analysis, tissue samples from 95 RCC patients who underwent radical nephrectomy were collected between June 2005 and January 2009, at the Department of Urology, Qilu Hospital, Shandong University, Jinan, China. None of the patients had received preoperative chemotherapy or radiotherapy. For survival analysis, more patients with advanced clinical stage were enrolled in this study. After surgery, 95 tumor samples and 14 normal renal tissues from the tumor bearing kidneys were fixed in formalin, embedded in paraffin and stored in the Department of Pathology, Qilu Hospital. For all samples, staging was reevaluated and determined according to the tumor node metastasis staging system [<xref rid="pone.0118659.ref017" ref-type="bibr">17</xref>], and the nuclear grade was evaluated on the basis of the Fuhrman four-grade scale [<xref rid="pone.0118659.ref018" ref-type="bibr">18</xref>]. All patients had their follow-up in the outpatient clinic of our department until April 2014. Patients without complete follow-up data were excluded from this study. Detailed clinicopathological information is listed in <xref rid="pone.0118659.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0118659.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.t001</object-id><label>Table 1</label><caption><title>Characteristics of the patients with RCC and correlations between subcellular pontin expression and clinicopathological variables (n = 95).</title></caption><alternatives><graphic id="pone.0118659.t001g" xlink:href="pone.0118659.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="center" colspan="1">Variables</th><th rowspan="2" align="center" colspan="1">No. of pts</th><th colspan="2" align="center" rowspan="1">Cytoplasmic pontin expression</th><th rowspan="2" align="center" colspan="1"><italic>P</italic>-value</th><th colspan="2" align="center" rowspan="1">Nuclear pontin expression</th><th rowspan="2" align="center" colspan="1"><italic>P</italic>-value</th></tr><tr><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th><th align="left" rowspan="1" colspan="1">High</th><th align="left" rowspan="1" colspan="1">Low</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Patients' age</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x02265; 55 Years</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0.511</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">29</td><td align="left" rowspan="1" colspan="1">0.229</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x0003c; 55 Years</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Gender</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Male</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">0.389</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">0.512</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Female</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>T stage</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;T<sub>1</sub></td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">0.057</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1">0.351</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;T<sub>2</sub></td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;T<sub>3</sub></td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;T<sub>4</sub></td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N stage</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;N<sub>0</sub></td><td align="left" rowspan="1" colspan="1">84</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">0.486</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">0.979</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;N<sub>1,2</sub></td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>M stage</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;M<sub>0</sub></td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">0.218</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;M<sub>1</sub></td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNM stage</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;I,II</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">0.003</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">0.594</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;III,IV</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">23</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1"><italic>Histological grade</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;G<sub>1,2</sub></td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">39</td><td align="left" rowspan="1" colspan="1">0.025</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">0.030</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;G<sub>3,4</sub></td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="2" align="left" rowspan="1"><italic>Histological type</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Clear cell</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">0.168</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">0.849</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Papillary</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Chromophobe</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;Unclassified</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Abbreviations: RCC = renal cell carcinoma.</p></fn></table-wrap-foot></table-wrap><p>For quantitative real-time PCR (qRT-PCR) and Western blotting analysis, 28 pairs of pathologically confirmed clear cell RCC (ccRCC) specimens (the tumor tissues and the matched normal renal tissues from the tumor bearing kidneys) were obtained during radical nephrectomy between July 2013 and October 2013 in our department. After surgery, every sample was immediately stored in liquid nitrogen until use.</p><p>Human RCC cell lines A498, 786-O and non-malignant-immortalized renal cell line HK-2 were purchased from ATCC (Manassas, VA, USA), and Human RCC cell line KRC/Y was obtained from the MTC-KI (Stockholm, Sweden) cell line collection [<xref rid="pone.0118659.ref019" ref-type="bibr">19</xref>]. HK-2 cells were cultured in KSFM medium (Gibco, USA), and other cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) containing 10% FBS (Invitrogen), 100 U/ml penicillin (Sigma, St. Louis, MO, USA), and 100 &#x003bc;g/ml streptomycin (Sigma). All cells were cultured in an incubator maintained at 37&#x000b0;C, 5% CO<sub>2</sub>.</p></sec><sec id="sec005"><title>Small interfering RNA treatment</title><p>The chemical modified siRNA targeting pontin and control siRNA were purchased from Invitrogen. The sequence of siRNA was pontin siRNA1: 5'-CCA UGC UGU AUA CUC CAC AGG AAA U-3' [<xref rid="pone.0118659.ref020" ref-type="bibr">20</xref>], and pontin siRNA2: 5'- TAA AGG AGA CCA AGG AAG T-3' [<xref rid="pone.0118659.ref005" ref-type="bibr">5</xref>]. Cells were transfected with either pontin or control siRNA with concentration of 100 nM using Lipofectamine 2000 (Invitrogen) following the manufacturer&#x02019;s instructions. The expression efficiencies were measured by quantitative RT-PCR and Western blotting.</p></sec><sec id="sec006"><title>RNA extraction, reverse transcription-PCR and quantitative real-time PCR</title><p>Total RNA was extracted from frozen surgical specimens and cell lines transfected for 48 h using Trizol reagent (Invitrogen), and reverse transcribed into cDNA using M-MLV reverse transcriptase (TaKaRa, Biotechnology, China). qRT-PCR was performed in a Mastercycler ep realplex real-time PCR system (Eppendorf, Hamburg, Germany) using SYBR Green kit (Applied Biosystems, Foster City, CA, USA) and the following primers: pontin, 5'-GGCATGTGGCGTCATAGTAGA-3' (Forward) and 5'- CACGGAGTTAGCTCTGTGACT-3' (Reverse), C-myc, 5&#x02019;-G-3&#x02019; (Forward) and 5&#x02019;-G-3&#x02019; (Reverse), Cyclin-D1: 5&#x02019;-G-3&#x02019; (Forward), and 5&#x02019;-G-3&#x02019; (Reverse) and <italic>&#x003b2;</italic>-actin: 5'-AGTTGCGTTACACCCTTTCTTG-3' (Forward) and 5'-CACCTTCACCGTTCCAGTTTT-3' (Reverse). <italic>&#x003b2;</italic>-actin was used as an internal control, and the relative pontin mRNA expression levels were analyzed using the 2<sup>-&#x00394;&#x00394;Ct</sup> method.</p></sec><sec id="sec007"><title>Immunohistochemistry</title><p>Immunohistochemistry was performed using a two-step protocol as we described previously [<xref rid="pone.0118659.ref016" ref-type="bibr">16</xref>]. The primary antibody used was anti-pontin (1:150; Abcam, Cambridge, MA, USA; Cat. No. ab51500). Color was developed with DAB Horseradish Peroxidase Color Development Kit (Beyotime, Haimen, China; Cat. No. P0202). Then the slides were counterstained with haematoxylin.</p></sec><sec id="sec008"><title>IHC evaluation and selection of the cutoff point</title><p>The slides were scored by 2 independent pathologists, who were blind to the patient characteristics. The cytoplasmic and nuclear pontin staining were evaluated separately by a semi-quantitative method considering both staining intensity (0, no staining of the tumor cells; 1, mild staining; 2, moderate staining and 3, strong staining) and the percentage of positive staining (0, 0&#x02013;5%; 1, 6%-25%; 2, 26%-50%; 3, 51%-75% and 4, &#x0003e;76%). The immunoreactive scores were determined by the sum of intensity and extension. Conflicting scores were resolved by consensus.</p><p>Because the immunoreactive scores of pontin showed neither a biphasic distribution nor a clear negative value, we determined the optimal cutoff point based on a heterogeneity value measured by log-rank test as literature reported [<xref rid="pone.0118659.ref021" ref-type="bibr">21</xref>]. Briefly, each staining index score from 1 to 7 was used as cutoff point, at each of these cutoff points, the patients were divided into two groups and the differences in OS were analyzed by log-rank test. The greatest difference between the two groups was at the staining index score 5. Therefore, this score was chosen as cutoff point for discrimination between pontin low and high expression.</p></sec><sec id="sec009"><title>Fluorescent immunocytochemical analysis</title><p>Cells were seeded onto coverslips, fixed and permeabilized with ice-cold methanol for 10 min. Then slides were blocked with 5% donkey serum, and incubated with mouse anti-pontin (1:100; Abcam) or mouse anti-<italic>&#x003b2;</italic>-catenin (1:100; BD Biosciences Pharmingen, San Jose, CA) antibodies overnight at 4&#x000b0;C. Afterwards, slides were immunostained with Fluor 488-conjugated donkey anti-mouse antibody for 1 hour at room temperature, followed by nuclear counterstaining with DAPI. Images were acquired using an epifluorescence microscopy (Nikon Eclipse TE 2000-U).</p></sec><sec id="sec010"><title>Western blotting analysis</title><p>Proteins extracted from frozen surgical specimens and cells transfected for 72 h were immunoblotted with different antibodies as we described previously [<xref rid="pone.0118659.ref016" ref-type="bibr">16</xref>]. The primary antibodies used were anti-pontin (1:100; Abcam), anti-E-cadherin (1:500; proteintech, Chicago, IL, USA; Cat. No. 20874-1-AP), anti-vimentin (1:1000; proteintech, Cat. No. 10366-1-AP) and anti-<italic>&#x003b2;</italic>-actin (Santa Cruz Biotechnologies, Santa Cruz, CA, USA).</p></sec><sec id="sec011"><title>Wound healing assay</title><p>Cells were seeded into 6-well plates the day before siRNA transfection. 24 h after transfection, similar sized wounds were made across the confluent cell monolayer with 200 &#x003bc;l pipette tips. The plates were washed twice to remove the detached cells and then incubated in serum-free medium for 24 h. Digital pictures were taken at 0 and 24 h after the scratch. The migration rate was calculated using the following formula: the radios of wound closure = decreased wound area at 24 h/wound area at 0 h.</p></sec><sec id="sec012"><title>Matrigel invasion assay</title><p>Cell invasion assay was performed using a 24-well transwell chamber with a pore size of 8 &#x003bc;m (Costar, NY, USA). The insert of the pore was coated with 50ul Matrigel (dilution at 1:2, BD Bioscience). Cells were trypsinized after transfection for 48 h and 1 &#x000d7; 10<sup>5</sup> cells were transferred to the upper chamber in 100 &#x003bc;l of serum-free medium. The lower chamber was filled with 1640 containing 10% FBS as chemoattractants. After incubation for 24 h, the non-invaded cells on the upper membrane surface were removed with a cotton swab, and the membranes were fixed and stained using 0.1% crystal violet. Representative fields were digitally captured and the invaded cells were counted in five randomly selected high-power fields (&#x000d7; 400) per filter to assess the average number of invaded cells.</p></sec><sec id="sec013"><title>Statistical analysis</title><p>The relative pontin expression level in the matched tumor and normal renal tissues was calculated using paired <italic>t</italic>-test. The correlations between subcellular pontin expression and the clinicopathological variables were analyzed using Chi-square test and Fisher&#x02019;s exact test. The survival analysis was evaluated using Kaplan-Meier method compared by the log-rank test. Multivariate Cox regression analysis was used to identify independent prognostic factors. The data of independent experiments <italic>in vitro</italic> were expressed as mean &#x000b1; s.e.m. and analyzed by Student&#x02019;s <italic>t</italic>-test. All statistical analyses were performed with SPSS 16.0 statistical software (Chicago, IL, USA). <italic>P</italic> value &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec014"><title>Results</title><sec id="sec015"><title>Expression of pontin and E-cadherin in clinical RCC samples</title><p>Expression of pontin mRNA and protein levels were detected using qRT-PCR and western blotting in 28 paired freshly frozen ccRCC tissues and the matched normal renal tissues. Pontin mRNA was significantly up-regulated in ccRCC tissues than in matched normal renal tissues (<italic>P</italic> = 0.0016, <xref rid="pone.0118659.g001" ref-type="fig">Fig. 1A</xref>). Consistent with the pontin mRNA expression profile, pontin protein was also increased in ccRCC tissues (<italic>P</italic> = 0.0095, <xref rid="pone.0118659.g001" ref-type="fig">Fig. 1B and D</xref>). Interestingly, we also found a significant decrease of the E-cadherin protein expression in ccRCC tissues, compared to the matched normal renal tissues (<italic>P</italic> &#x0003c; 0.001, <xref rid="pone.0118659.g001" ref-type="fig">Fig. 1C and D</xref>).</p><fig id="pone.0118659.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.g001</object-id><label>Fig 1</label><caption><title>Pontin and E-cadherin expression profiles in 28 pairs of ccRCC tissues and the matched normal renal tissues.</title><p>(A) Relative pontin mRNA levels determined by qRT-PCR. (B and C) Relative pontin and E-cadherin protein levels determined by western blotting analyses. (D) Western blotting analyses from 4 representative pairs of matched ccRCC and normal renal tissues. <italic>&#x003b2;</italic>-actin was used as a loading control. **<italic>P</italic>&#x0003c;0.01, ***<italic>P</italic>&#x0003c;0.001.</p></caption><graphic xlink:href="pone.0118659.g001"/></fig></sec><sec id="sec016"><title>Subcellular pontin expression and the clinicopathological variables of RCC patients</title><p>We further analyzed pontin protein expressions in a set of 95 RCC surgical specimens and 14 tumor adjacent renal tissues using an immunohistochemical approach. Representative staining of pontin is shown in <xref rid="pone.0118659.g002" ref-type="fig">Fig. 2A-M</xref>. The presence of pontin protein was found in 87 of 95 (91.6%) RCC samples, and pontin protein expression was highly expressed in 38 out of the 87 (43.7%) pontin-positive RCC patients, whereas only weak to moderate pontin staining was found in 8 of 14 (57.1%) tumor adjacent renal tissues. In addition, positive staining for pontin was observed both in cytoplasm and in nucleus (<xref rid="pone.0118659.g002" ref-type="fig">Fig. 2A-H</xref>). Interestingly, among the 95 RCC specimens there are 5 samples presented with both the tumor tissues and the tumorous invasive margin, and strong cytoplasmic staining of pontin was observed at all of the tumorous invasive margin (<xref rid="pone.0118659.g002" ref-type="fig">Fig. 2I and J</xref>). However, only a diffuse pontin staining was observed in the proximal tubules of normal renal tissues, and predominantly localized in nucleus (<xref rid="pone.0118659.g002" ref-type="fig">Fig. 2K and L</xref>). In addition, fluorescent immunocytochemical analysis showed pontin expression was predominantly localized in the cytoplasm of RCC cell lines A498 and 786-O, while a weak nuclear pontin expression was observed in the normal renal epithelial cell line HK-2 (<xref rid="pone.0118659.g002" ref-type="fig">Fig. 2N</xref>), which was in accord with the IHC observation.</p><fig id="pone.0118659.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.g002</object-id><label>Fig 2</label><caption><title>Immuno staining of pontin in RCC surgical specimens and cell lines.</title><p>Strong cytoplasmic staining of pontin in clear cell RCC (A and B), papillary RCC (E and F), and chromophobe RCC (G and H). Strong nuclear staining of pontin in clear cell RCC (C and D, arrow shows the cells with a strong nuclear staining). Strong cytoplasmic staining of pontin in the tumorous invasive margin of clear cell RCC, while no pontin staining or predominantly nuclear pontin staining in tumor adjacent renal tissues (I and J, &#x02605;: glomerulus of the tumor adjacent renal tissues; &#x025b2;: infiltrating lymphocytes). Diffuse pontin staining in the proximal tubules of normal renal tissues (K and L). Negative control of clear cell RCC (M). Subcellular localization of pontin protein in RCC cell lines A498, 786-O and normal renal epithelial cell line HK-2 detected by fluorescent immunocytochemical analysis (N). Magnification: A, C, E, G, I, K: &#x000d7;100; B, D, F, H, J, L, M: &#x000d7;400 and N: &#x000d7;600.</p></caption><graphic xlink:href="pone.0118659.g002"/></fig><p>Because of the different IHC staining pattern of pontin in RCC tissues, as compared with the tumor adjacent renal tissues, cytoplasmic and nuclear pontin staining were scored separately, and its significance with respect to the main clinicopathological variables was evaluated (<xref rid="pone.0118659.t001" ref-type="table">Table 1</xref>). Patients with high cytoplasmic pontin expression exhibited a significant association with advanced clinical stage (<italic>P</italic> = 0.003), poor histological grade (<italic>P</italic> = 0.025) and distant metastasis (<italic>P</italic> = 0.010). In contrast, we only found one significant association between high nuclear pontin expression and poor histological grade (<italic>P</italic> = 0.030). Furthermore, no significant associations between pontin expression and patients&#x02019; gender, age or histological type was observed.</p></sec><sec id="sec017"><title>Subcellular pontin expression and postoperative survival of RCC patients</title><p>Of the total number of patients, 25 (26.3%) patients died of RCC with a median follow-up time of 24 months (11&#x0223c;84 months), and the remaining 70 (73.7%) patients were alive with a median follow-up time of 92 months (54&#x0223c;106 months). Kaplan-Meier analysis compared by the log-rank test was used to evaluate the effects of the clinicopathological variables on overall survival (OS). Univariate analysis indicated that patients with advanced primary tumor stage, lymph nodes metastasis, distant metastasis, high histological grade and advanced clinical stage exhibited worse outcomes (all <italic>P</italic> &#x0003c;0.01; <xref rid="pone.0118659.t002" ref-type="table">Table 2</xref>). And a significant lower OS rate in patients with high cytoplasmic pontin expression was observed as compared to those with a low level (85.5% <italic>vs</italic>. 42.3%, <italic>P</italic> &#x0003c; 0.001; <xref rid="pone.0118659.g003" ref-type="fig">Fig. 3A</xref>). However, there was no significant difference in terms of OS between high and low nuclear pontin expression (<italic>P</italic> = 0.439; <xref rid="pone.0118659.g003" ref-type="fig">Fig. 3B</xref>). In addition, multivariate analysis indicated that advanced clinical stage, high histological grade and high cytoplasmic pontin expression were independent prognostic factors for RCC patients (<xref rid="pone.0118659.t002" ref-type="table">Table 2</xref>).</p><fig id="pone.0118659.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.g003</object-id><label>Fig 3</label><caption><title>Kaplan-Meier curves of overall survival stratified by cytoplasmic pontin expression status.</title><p>(A) and nuclear pontin expression status (B). <italic>P</italic>-value was calculated by log-rank test.</p></caption><graphic xlink:href="pone.0118659.g003"/></fig><table-wrap id="pone.0118659.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.t002</object-id><label>Table 2</label><caption><title>Univariate and Multivariate analyses for overall survival of 95 RCC patients.</title></caption><alternatives><graphic id="pone.0118659.t002g" xlink:href="pone.0118659.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="center" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Univariate analysis</th><th colspan="3" align="center" rowspan="1">Multivariate analysis</th></tr><tr><th align="left" rowspan="1" colspan="1">Survival rate</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th><th align="left" rowspan="1" colspan="1">HR</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients' age (&#x02265;55 yrs vs &#x0003c; 55 yrs)</td><td align="left" rowspan="1" colspan="1">77.2% vs 68.4%</td><td align="left" rowspan="1" colspan="1">0.518</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">T stage (T<sub>1,2</sub> vs T<sub>3,4</sub>)</td><td align="left" rowspan="1" colspan="1">93.7% vs 34.4%</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="left" rowspan="1" colspan="1">0.79</td><td align="left" rowspan="1" colspan="1">0.367&#x02013;2.720</td><td align="left" rowspan="1" colspan="1">0.559</td></tr><tr><td align="left" rowspan="1" colspan="1">N stage (N<sub>0</sub> vs N<sub>1,2</sub>)</td><td align="left" rowspan="1" colspan="1">78.6% vs 36.4%</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">1.19</td><td align="left" rowspan="1" colspan="1">0.351&#x02013;4.048</td><td align="left" rowspan="1" colspan="1">0.778</td></tr><tr><td align="left" rowspan="1" colspan="1">M stage (M<sub>0</sub> vs M<sub>1,2</sub>)</td><td align="left" rowspan="1" colspan="1">84.3% vs 0</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="left" rowspan="1" colspan="1">3.65</td><td align="left" rowspan="1" colspan="1">0.769&#x02013;17.336</td><td align="left" rowspan="1" colspan="1">0.103</td></tr><tr><td align="left" rowspan="1" colspan="1">TNM stage (I, II vs III, IV)</td><td align="left" rowspan="1" colspan="1">100% vs 35.9%</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="left" rowspan="1" colspan="1">7.94</td><td align="left" rowspan="1" colspan="1">2.277&#x02013;27.708</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological grade (G<sub>1,2</sub> vs G<sub>3,4</sub>)</td><td align="left" rowspan="1" colspan="1">89.4% vs 58.3%</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">2.39</td><td align="left" rowspan="1" colspan="1">1.194&#x02013;4.801</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Cytoplasmic pontin expression (Low vs High)</td><td align="left" rowspan="1" colspan="1">85.5% vs 42.3%</td><td align="left" rowspan="1" colspan="1">&#x0003c; 0.001</td><td align="left" rowspan="1" colspan="1">2.67</td><td align="left" rowspan="1" colspan="1">1.124&#x02013;6.337</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">Nuclear pontin expression (Low vs High)</td><td align="left" rowspan="1" colspan="1">75.6% vs 64.7%</td><td align="left" rowspan="1" colspan="1">0.439</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Abbreviations: RCC = renal cell carcinoma; HR = hazard radio; CI = confidence interval.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Effects of pontin depletion on cell migration and invasion</title><p>Pontin mRNA and protein expression was remarkably inhibited in A498, 786-O and KRC/Y cells treated with pontin siRNA1 compared with the control siRNA group (<xref rid="pone.0118659.g004" ref-type="fig">Fig. 4A and B</xref>). Then we studied the effects of pontin depletion on cell migration and invasion using would healing assay and Matrigel invasion assay. The potential effect of cell proliferation on cell migration and invasion was rolled out (<xref rid="pone.0118659.s001" ref-type="supplementary-material">S1 Fig.</xref>). The migratory capacity of pontin siRNA1 treated cells was significantly decreased at 24 h after scratch (the radios of wound closure: control <italic>vs</italic>. pontin siRNA1, A498: 0.626 &#x000b1; 0.030 <italic>vs</italic>. 0.128 &#x000b1; 0.022, <italic>P</italic> &#x0003c; 0.0001; 786-O: 0.635 &#x000b1; 0.020 <italic>vs</italic>. 0.058 &#x000b1; 0.011, <italic>P</italic> &#x0003c; 0.0001; KRC/Y: 0.440 &#x000b1; 0.022 <italic>vs</italic>. 0.037 &#x000b1; 0.013, <italic>P</italic> &#x0003c; 0.0001) (<xref rid="pone.0118659.g004" ref-type="fig">Fig. 4C and D</xref>). In addition, Matrigel invasion assay revealed that the number of invaded cells penetrating through the filter was significantly reduced following pontin depletion in A498 (the number of invaded cells per field: control <italic>vs</italic>. pontin siRNA1: 80.67 &#x000b1; 3.64 <italic>vs</italic>. 15.67 &#x000b1; 1.74, <italic>P</italic> &#x0003c; 0.0001), 786-O (87.67 &#x000b1; 9.67 <italic>vs</italic>. 5.00 &#x000b1; 1.15, <italic>P</italic> &#x0003c; 0.0001) and KRC/Y (77.50 &#x000b1; 3.18 <italic>vs</italic>. 14.33 &#x000b1; 1.67, <italic>P</italic> &#x0003c; 0.0001) (<xref rid="pone.0118659.g004" ref-type="fig">Fig. 4E and F</xref>). Additionally, we examine the potential off target effects of pontin siRNA1 by introducing a nonoverlapping pontin siRNA2. The results ruled out the nonspecific off target effects of the siRNA approach (<xref rid="pone.0118659.s002" ref-type="supplementary-material">S2 Fig.</xref>).</p><fig id="pone.0118659.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.g004</object-id><label>Fig 4</label><caption><title>Effects of pontin depletion on RCC cell migration/invasion activities <italic>in vitro</italic>.</title><p>(A) Effects on the pontin mRNA expression after siRNA transfection for 48 h detected by semi-quantitative RT-PCR. (B) Effects on the pontin protein expression after siRNA transfection for 72 h detected by western blotting. (C and D) Migration capacity of RCC cells were examined by wound healing assay. (E and F) Invasion capacity of RCC cells were examined by Matrigel invasion assay. Data were shown as mean &#x000b1; s.e.m. (n = 3) ***<italic>P</italic>&#x0003c;0.001.</p></caption><graphic xlink:href="pone.0118659.g004"/></fig></sec><sec id="sec019"><title>Effects of pontin depletion on the expression of E-cadherin and vimentin, and &#x003b2;-catenin localization</title><p>Previous studies demonstrated that the epithelial-to-mesenchymal transition (EMT) is a crucial step for epithelial cancer progression. We hypothesized that pontin might regulate the metastatic progression of RCC through EMT pathway, and investigate the potential effect of pontin on E-cadherin, vimentin protein expression. The results revealed that E-cadherin was dramatically increased in the pontin siRNA1 treated cells as compared with the control siRNA group, while vimentin was significantly decreased following the pontin depletion (<xref rid="pone.0118659.g005" ref-type="fig">Fig. 5A</xref>).</p><fig id="pone.0118659.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0118659.g005</object-id><label>Fig 5</label><caption><title>Effects of pontin depletion on the expression of E-cadherin and vimentin, and <italic>&#x003b2;</italic>-catenin subcellular localization <italic>in vitro</italic>.</title><p>(A) Effects on the protein expression of pontin, E-cadherin and vimentin after siRNA transfection for 72 h detected by western blotting. The data shown is representative of 3 independent experiments. (B) The subcellular location of <italic>&#x003b2;</italic>-catenin was measured by fluorescent immunocytochemical analysis after siRNA transfection for 72 h (green, &#x003b2;-catenin; blue, DAPI nuclear staining). Magnification: &#x000d7;600. (C) Time dependent changes in mRNA levels of pontin, c-myc and cyclin D1 after siRNA transfection for 48h, 72h and 96h detected by qRT-PCT. Data were shown as mean &#x000b1; s.e.m. (n = 3). <italic>&#x003b2;</italic>-actin was used as a loading control. *<italic>P</italic>&#x0003c;0.05, **<italic>P</italic>&#x0003c;0.01, ***<italic>P</italic>&#x0003c;0.001.</p></caption><graphic xlink:href="pone.0118659.g005"/></fig><p>Furthermore, we investigate the potential effect of pontin depletion on <italic>&#x003b2;</italic>-catenin. Fluorescence immunocytochemical analysis revealed that nuclear <italic>&#x003b2;</italic>-catenin was significantly decreased in the pontin siRNA1 treated cells than in the control siRNA group (<xref rid="pone.0118659.g005" ref-type="fig">Fig. 5B</xref>). In consistence, qRT-PCR results demonstrated a significant decrease of the mRNA levels of 2 canonical <italic>&#x003b2;</italic>-catenin target gene c-myc [<xref rid="pone.0118659.ref022" ref-type="bibr">22</xref>] and cyclin D1 [<xref rid="pone.0118659.ref023" ref-type="bibr">23</xref>] in pontin siRNA1 treated group in a time-dependent manner, compared with the control siRNA group (<xref rid="pone.0118659.g005" ref-type="fig">Fig. 5C</xref>), indicating the potential effect of pontin on <italic>&#x003b2;</italic>-catenin nuclear translocation.</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>Recent studies have implicated the AAA+ superfamily member pontin and its homology reptin are involved in many cellular processes that are highly relevant to cancer. Both proteins interact with some major oncogenic factors such as <italic>&#x003b2;</italic>-catenin and c-myc, and regulate their oncogenic functions [<xref rid="pone.0118659.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0118659.ref008" ref-type="bibr">8</xref>]. Several studies revealed aberrant expression of pontin and reptin in some human progressive malignancies: both pontin and reptin are overexpressed in hepatocellular carcinoma [<xref rid="pone.0118659.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0118659.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0118659.ref024" ref-type="bibr">24</xref>], pontin overexpression are reported in colorectal [<xref rid="pone.0118659.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0118659.ref014" ref-type="bibr">14</xref>], prostate [<xref rid="pone.0118659.ref025" ref-type="bibr">25</xref>], and non-small cell lung cancers [<xref rid="pone.0118659.ref026" ref-type="bibr">26</xref>], reptin overexpression are reported in breast [<xref rid="pone.0118659.ref015" ref-type="bibr">15</xref>], gastric [<xref rid="pone.0118659.ref020" ref-type="bibr">20</xref>], and bladder cancers [<xref rid="pone.0118659.ref027" ref-type="bibr">27</xref>]. To the best of our knowledge, there are few studies focused on the role of pontin in RCC, and the molecular mechanism of pontin participating in tumor metastatic progression has so far not been elucidated.</p><p>Our study is the first report showing that pontin overexpression widely occurs in kidney cancer. We observed a 2 to 3 fold higher expression of pontin mRNA and protein in tumor tissues than in the matched normal renal tissues in 28 paired clear cell RCC samples. In consistence, IHC staining showed an intense staining of pontin in 91.6% of RCC tissues, especially at the tumorous invasive margin, while only a diffuse pontin staining in proximal tubules was observed in the normal renal tissues. However, the mechanism for the up-regulation of pontin and reptin in cancer remains currently unclear. Pontin gene lies on chromosome 3q21, a region commonly amplified in non-small cell lung cancer, which indicates that pontin overexpression may be due to gene amplification [<xref rid="pone.0118659.ref026" ref-type="bibr">26</xref>]. But that region is not commonly affected in HCC, colorectal cancer, or RCC, thus it is unlikely that pontin up-regulation is consecutive to gene amplification in these cancers. Further study needs to be done to elucidate the molecular mechanisms of pontin overexpression in RCC.</p><p>Statistical analysis of the clinicopathological features of RCC patients in our study revealed that high cytoplasmic pontin expression was significantly associated with the aggressive features of RCC. Kim <italic>et al</italic> reported that reptin depletion reduced invasive capacity of the prostatic LNCap cells, which is in accord with the requirement of reptin in the repression of the anti-metastatic gene KAI1 [<xref rid="pone.0118659.ref028" ref-type="bibr">28</xref>]. However, to the best of our knowledge, the effects of pontin on migration and invasion of cancer cells remains unclear, except that Cram <italic>et al</italic> using systemic RNAi screen identified pontin as a member of a cell migration gene network in Caenorhabditis elegans [<xref rid="pone.0118659.ref029" ref-type="bibr">29</xref>]. Our study firstly demonstrated that pontin depletion by siRNA significantly inhibited the migration and invasion capacity of RCC cell lines <italic>in vitro</italic>.</p><p>Along our efforts to explore the mechanism of the pro-migratory and pro-invasive role of pontin in RCC, we observed a significantly decreased expression of E-cadherin in ccRCC tissues. Concomitantly, a dramatic increase of E-cadherin expression and a significant decrease of vimentin expression in RCC cell lines following pontin depletion was observed, suggesting the involvement of EMT in the pro-migratory and pro-invasive effect of pontin. For epithelial malignances, EMT is considered to be an essential step in cancer dissemination and metastatic progression [<xref rid="pone.0118659.ref030" ref-type="bibr">30</xref>]. E-cadherin is a marker of the epithelial-like phenotype. Loss of E-cadherin is a hallmark of EMT, which leads to disassembly of adherens junctions, and enhances motility and invasion of tumor cells [<xref rid="pone.0118659.ref031" ref-type="bibr">31</xref>]. <italic>&#x003b2;</italic>-catenin is a component of the adherens junctions. It is known that pontin has an agonistic effect on the transcription of the positive targets of <italic>&#x003b2;</italic>-catenin [<xref rid="pone.0118659.ref008" ref-type="bibr">8</xref>], which is one of the main pathways of pontin involving in carcinogenesis. Whitehead <italic>et al</italic> demonstrated that <italic>&#x003b2;</italic>-catenin phosphorylation induced by mechanical stimulation at tyrosine 654, the site of its interaction with E-cadherin, could increase the nuclear localization of <italic>&#x003b2;</italic>-catenin, up-regulating the transcription of oncogenes Myc and Twist1 [<xref rid="pone.0118659.ref032" ref-type="bibr">32</xref>]. Our results that the nuclear <italic>&#x003b2;</italic>-catenin was significantly decreased following pontin depletion supported the hypothesis that pontin may regulate <italic>&#x003b2;</italic>-catenin by relocating it from the adherens junctions in cytoplasm to the transcriptional complexes in nucleus through EMT process. Our data suggest that siRNA-mediated pontin depletion in RCC cell lines revoke the pontin-induced down-regulation of E-cadherin, and subsequently increased the binding capacity of the adherens junctions for <italic>&#x003b2;</italic>-catenin, leaving less <italic>&#x003b2;</italic>-catenin transferred to the transcriptional complexes in nucleus, inhibiting the transcription of the down-stream oncogenes. Above observations is in accord with the findings by Lauscher <italic>et al</italic> that nuclear co-localization of pontin and <italic>&#x003b2;</italic>-catenin was associated with progression of colorectal carcinomas [<xref rid="pone.0118659.ref014" ref-type="bibr">14</xref>]. However, further studies needs to be done to elucidate the molecular mechanisms involved in the pontin-induced down-regulation of E-cadherin.</p><p>Given that all main effects of pontin and reptin are associated with the interactions with multi-protein complexes in nucleus, Lauscher <italic>et al</italic> focused on the nuclear expression of pontin, albeit they found cytoplasmic pontin staining in the majority of colon cancer samples (&#x0003e; 76%) through IHC staining. And they failed to find any correlations between positive nuclear pontin staining and recurrence-free survival or overall survival [<xref rid="pone.0118659.ref013" ref-type="bibr">13</xref>]. In this context, however, one of the highlighted findings is that we first reported the evaluation of subcellular expression of pontin in human RCC, and demonstrated that pontin overexpression in cytoplasm, rather than in nucleus, significantly correlated with RCC metastatic progression. These observations, together with our previous study on reptin [<xref rid="pone.0118659.ref016" ref-type="bibr">16</xref>], strongly indicated that pontin and reptin may have distinct carcinogenic effects localizing in cytoplasm, independent of their known roles in nucleus. Study on HCC also revealed definite cytoplasmic reptin expression in all analyzed HCCs [<xref rid="pone.0118659.ref024" ref-type="bibr">24</xref>], suggesting additional oncogenic properties of reptin in cytoplasm.</p><p>In summary, this study for the first time identified pontin up-regulated in RCC and high cytoplasmic pontin expression was associated with poor survival of RCC patients. <italic>In vitro</italic> experiments suggest that pontin may play a previously unknown pro-invasive role in the metastatic progression of RCC through EMT pathway. Therefore, these results warrant further investigation of pontin as a potential therapeutic target in developing more effective treatment of RCC.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0118659.s001"><label>S1 Fig</label><caption><title>Effects of pontin depletion on RCC cell proliferation in 24-hour serum-free medium culture.</title><p>A498 and 786-O cell numbers were counted in 4 randomly selected high-power fields (&#x000d7; 400) per well in the same condition as for migration assay. No significant difference of the cell number between pontin siRNA1 group and the control siRNA group. Data were shown as mean &#x000b1; s.e.m. (n = 3)</p><p>(TIF)</p></caption><media xlink:href="pone.0118659.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0118659.s002"><label>S2 Fig</label><caption><title>Effects of pontin depletion on RCC cell migration/invasion activities <italic>in vitro</italic>.</title><p>(A) Effects on the pontin mRNA expression after siRNA transfection for 48 h detected by semi-quantitative RT-PCR. Pontin mRNA was remarkably inhibited in A498 and 786-O treated with pontin siRNA2 compared with the control siRNA group. (B and C) Migration capacity of RCC cells were examined by wound healing assay. The migratory capacity of pontin siRNA2 treated A498 and 786-O was significantly decreased at 24 h after the scratch (both <italic>P</italic> &#x0003c; 0.001). (D and E) Invasion capacity of RCC cells were examined by Matrigel invasion assay. The invasive capacity of pontin siRNA2 treated A498 and 786-O was significantly decreased as compared with the control siRNA group (both <italic>P</italic> &#x0003c; 0.001). Data were shown as mean &#x000b1; s.e.m. (n = 3) ***<italic>P</italic>&#x0003c;0.001.</p><p>(TIF)</p></caption><media xlink:href="pone.0118659.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0118659.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Eisengart</surname><given-names>LJ</given-names></name>, <name><surname>MacVicar</surname><given-names>GR</given-names></name>, <name><surname>Yang</surname><given-names>XJ</given-names></name>
<article-title>Predictors of response to targeted therapy in renal cell carcinoma</article-title>. <source>Archives of pathology &#x00026; laboratory medicine</source>. <year>2012</year>;<volume>136</volume>(<issue>5</issue>):<fpage>490</fpage>&#x02013;<lpage>5</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5858/arpa.2010-0308-RA">10.5858/arpa.2010-0308-RA</ext-link></comment><object-id pub-id-type="pmid">22229848</object-id>.<pub-id pub-id-type="pmid">22229848</pub-id></mixed-citation></ref><ref id="pone.0118659.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Grigoletto</surname><given-names>A</given-names></name>, <name><surname>Lestienne</surname><given-names>P</given-names></name>, <name><surname>Rosenbaum</surname><given-names>J</given-names></name>
<article-title>The multifaceted proteins Reptin and Pontin as major players in cancer</article-title>. <source>Biochimica et biophysica acta</source>. <year>2011</year>;<volume>1815</volume>(<issue>2</issue>):<fpage>147</fpage>&#x02013;<lpage>57</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbcan.2010.11.002">10.1016/j.bbcan.2010.11.002</ext-link></comment><object-id pub-id-type="pmid">21111787</object-id>.<pub-id pub-id-type="pmid">21111787</pub-id></mixed-citation></ref><ref id="pone.0118659.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Jin</surname><given-names>J</given-names></name>, <name><surname>Cai</surname><given-names>Y</given-names></name>, <name><surname>Yao</surname><given-names>T</given-names></name>, <name><surname>Gottschalk</surname><given-names>AJ</given-names></name>, <name><surname>Florens</surname><given-names>L</given-names></name>, <name><surname>Swanson</surname><given-names>SK</given-names></name>, <etal>et al</etal>
<article-title>A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex</article-title>. <source>The Journal of biological chemistry</source>. <year>2005</year>;<volume>280</volume>(<issue>50</issue>):<fpage>41207</fpage>&#x02013;<lpage>12</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1074/jbc.M509128200">10.1074/jbc.M509128200</ext-link></comment><object-id pub-id-type="pmid">16230350</object-id>.<pub-id pub-id-type="pmid">16230350</pub-id></mixed-citation></ref><ref id="pone.0118659.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Gallant</surname><given-names>P</given-names></name>
<article-title>Control of transcription by Pontin and Reptin</article-title>. <source>Trends in cell biology</source>. <year>2007</year>;<volume>17</volume>(<issue>4</issue>):<fpage>187</fpage>&#x02013;<lpage>92</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tcb.2007.02.005">10.1016/j.tcb.2007.02.005</ext-link></comment><object-id pub-id-type="pmid">17320397</object-id>.<pub-id pub-id-type="pmid">17320397</pub-id></mixed-citation></ref><ref id="pone.0118659.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Jha</surname><given-names>S</given-names></name>, <name><surname>Shibata</surname><given-names>E</given-names></name>, <name><surname>Dutta</surname><given-names>A</given-names></name>
<article-title>Human Rvb1/Tip49 is required for the histone acetyltransferase activity of Tip60/NuA4 and for the downregulation of phosphorylation on H2AX after DNA damage</article-title>. <source>Molecular and cellular biology</source>. <year>2008</year>;<volume>28</volume>(<issue>8</issue>):<fpage>2690</fpage>&#x02013;<lpage>700</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/MCB.01983-07">10.1128/MCB.01983-07</ext-link></comment><object-id pub-id-type="pmid">18285460</object-id>; PubMed Central PMCID: PMC2293106.<pub-id pub-id-type="pmid">18285460</pub-id></mixed-citation></ref><ref id="pone.0118659.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Boulon</surname><given-names>S</given-names></name>, <name><surname>Marmier-Gourrier</surname><given-names>N</given-names></name>, <name><surname>Pradet-Balade</surname><given-names>B</given-names></name>, <name><surname>Wurth</surname><given-names>L</given-names></name>, <name><surname>Verheggen</surname><given-names>C</given-names></name>, <name><surname>Jady</surname><given-names>BE</given-names></name>, <etal>et al</etal>
<article-title>The Hsp90 chaperone controls the biogenesis of L7Ae RNPs through conserved machinery</article-title>. <source>The Journal of cell biology</source>. <year>2008</year>;<volume>180</volume>(<issue>3</issue>):<fpage>579</fpage>&#x02013;<lpage>95</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.200708110">10.1083/jcb.200708110</ext-link></comment><object-id pub-id-type="pmid">18268104</object-id>; PubMed Central PMCID: PMC2234240.<pub-id pub-id-type="pmid">18268104</pub-id></mixed-citation></ref><ref id="pone.0118659.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Wood</surname><given-names>MA</given-names></name>, <name><surname>McMahon</surname><given-names>SB</given-names></name>, <name><surname>Cole</surname><given-names>MD</given-names></name>
<article-title>An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc</article-title>. <source>Molecular cell</source>. <year>2000</year>;<volume>5</volume>(<issue>2</issue>):<fpage>321</fpage>&#x02013;<lpage>30</lpage>
<object-id pub-id-type="pmid">10882073</object-id>.<pub-id pub-id-type="pmid">10882073</pub-id></mixed-citation></ref><ref id="pone.0118659.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>A</given-names></name>, <name><surname>Chauvet</surname><given-names>S</given-names></name>, <name><surname>Huber</surname><given-names>O</given-names></name>, <name><surname>Usseglio</surname><given-names>F</given-names></name>, <name><surname>Rothbacher</surname><given-names>U</given-names></name>, <name><surname>Aragnol</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Pontin52 and reptin52 function as antagonistic regulators of beta-catenin signalling activity</article-title>. <source>The EMBO journal</source>. <year>2000</year>;<volume>19</volume>(<issue>22</issue>):<fpage>6121</fpage>&#x02013;<lpage>30</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/emboj/19.22.6121">10.1093/emboj/19.22.6121</ext-link></comment><object-id pub-id-type="pmid">11080158</object-id>; PubMed Central PMCID: PMC305835.<pub-id pub-id-type="pmid">11080158</pub-id></mixed-citation></ref><ref id="pone.0118659.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Lee</surname><given-names>N</given-names></name>, <name><surname>Fearon</surname><given-names>ER</given-names></name>
<article-title>TIP49 regulates beta-catenin-mediated neoplastic transformation and T-cell factor target gene induction via effects on chromatin remodeling</article-title>. <source>Cancer research</source>. <year>2003</year>;<volume>63</volume>(<issue>24</issue>):<fpage>8726</fpage>&#x02013;<lpage>34</lpage>
<object-id pub-id-type="pmid">14695187</object-id>.<pub-id pub-id-type="pmid">14695187</pub-id></mixed-citation></ref><ref id="pone.0118659.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Haurie</surname><given-names>V</given-names></name>, <name><surname>Menard</surname><given-names>L</given-names></name>, <name><surname>Nicou</surname><given-names>A</given-names></name>, <name><surname>Touriol</surname><given-names>C</given-names></name>, <name><surname>Metzler</surname><given-names>P</given-names></name>, <name><surname>Fernandez</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism</article-title>. <source>Hepatology</source>. <year>2009</year>;<volume>50</volume>(<issue>6</issue>):<fpage>1871</fpage>&#x02013;<lpage>83</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/hep.23215">10.1002/hep.23215</ext-link></comment><object-id pub-id-type="pmid">19877184</object-id>; PubMed Central PMCID: PMC2927003.<pub-id pub-id-type="pmid">19877184</pub-id></mixed-citation></ref><ref id="pone.0118659.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Menard</surname><given-names>L</given-names></name>, <name><surname>Taras</surname><given-names>D</given-names></name>, <name><surname>Grigoletto</surname><given-names>A</given-names></name>, <name><surname>Haurie</surname><given-names>V</given-names></name>, <name><surname>Nicou</surname><given-names>A</given-names></name>, <name><surname>Dugot-Senant</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>In vivo silencing of Reptin blocks the progression of human hepatocellular carcinoma in xenografts and is associated with replicative senescence</article-title>. <source>Journal of hepatology</source>. <year>2010</year>;<volume>52</volume>(<issue>5</issue>):<fpage>681</fpage>&#x02013;<lpage>9</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jhep.2009.12.029">10.1016/j.jhep.2009.12.029</ext-link></comment><object-id pub-id-type="pmid">20346530</object-id>.<pub-id pub-id-type="pmid">20346530</pub-id></mixed-citation></ref><ref id="pone.0118659.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Berasain</surname><given-names>C</given-names></name>
<article-title>New therapeutic targets in HCC: reptin ATPase and HCC senescence</article-title>. <source>Journal of hepatology</source>. <year>2010</year>;<volume>52</volume>(<issue>5</issue>):<fpage>633</fpage>&#x02013;<lpage>4</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jhep.2010.01.020">10.1016/j.jhep.2010.01.020</ext-link></comment><object-id pub-id-type="pmid">20334944</object-id>.<pub-id pub-id-type="pmid">20334944</pub-id></mixed-citation></ref><ref id="pone.0118659.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Lauscher</surname><given-names>JC</given-names></name>, <name><surname>Elezkurtaj</surname><given-names>S</given-names></name>, <name><surname>Dullat</surname><given-names>S</given-names></name>, <name><surname>Lipka</surname><given-names>S</given-names></name>, <name><surname>Grone</surname><given-names>J</given-names></name>, <name><surname>Buhr</surname><given-names>HJ</given-names></name>, <etal>et al</etal>
<article-title>Increased Pontin expression is a potential predictor for outcome in sporadic colorectal carcinoma</article-title>. <source>Oncology reports</source>. <year>2012</year>;<volume>28</volume>(<issue>5</issue>):<fpage>1619</fpage>&#x02013;<lpage>24</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3892/or.2012.1968">10.3892/or.2012.1968</ext-link></comment><object-id pub-id-type="pmid">22895545</object-id>.<pub-id pub-id-type="pmid">22895545</pub-id></mixed-citation></ref><ref id="pone.0118659.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Lauscher</surname><given-names>JC</given-names></name>, <name><surname>Loddenkemper</surname><given-names>C</given-names></name>, <name><surname>Kosel</surname><given-names>L</given-names></name>, <name><surname>Grone</surname><given-names>J</given-names></name>, <name><surname>Buhr</surname><given-names>HJ</given-names></name>, <name><surname>Huber</surname><given-names>O</given-names></name>
<article-title>Increased pontin expression in human colorectal cancer tissue</article-title>. <source>Human pathology</source>. <year>2007</year>;<volume>38</volume>(<issue>7</issue>):<fpage>978</fpage>&#x02013;<lpage>85</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.humpath.2007.01.005">10.1016/j.humpath.2007.01.005</ext-link></comment><object-id pub-id-type="pmid">17442372</object-id>.<pub-id pub-id-type="pmid">17442372</pub-id></mixed-citation></ref><ref id="pone.0118659.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Maslon</surname><given-names>MM</given-names></name>, <name><surname>Hrstka</surname><given-names>R</given-names></name>, <name><surname>Vojtesek</surname><given-names>B</given-names></name>, <name><surname>Hupp</surname><given-names>TR</given-names></name>
<article-title>A divergent substrate-binding loop within the pro-oncogenic protein anterior gradient-2 forms a docking site for Reptin</article-title>. <source>Journal of molecular biology</source>. <year>2010</year>;<volume>404</volume>(<issue>3</issue>):<fpage>418</fpage>&#x02013;<lpage>38</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jmb.2010.09.035">10.1016/j.jmb.2010.09.035</ext-link></comment><object-id pub-id-type="pmid">20888340</object-id>.<pub-id pub-id-type="pmid">20888340</pub-id></mixed-citation></ref><ref id="pone.0118659.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Ren</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Yan</surname><given-names>L</given-names></name>, <name><surname>Jiao</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Overexpression of reptin in renal cell carcinoma contributes to tumor malignancies and its inhibition triggers senescence of cancer cells</article-title>. <source>Urologic oncology</source>. <year>2013</year>;<volume>31</volume>(<issue>7</issue>):<fpage>1358</fpage>&#x02013;<lpage>66</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.urolonc.2012.01.004">10.1016/j.urolonc.2012.01.004</ext-link></comment><object-id pub-id-type="pmid">22341977</object-id>.<pub-id pub-id-type="pmid">22341977</pub-id></mixed-citation></ref><ref id="pone.0118659.ref017"><label>17</label><mixed-citation publication-type="book"><name><surname>Eble</surname><given-names>J</given-names></name>, <name><surname>Sauter</surname><given-names>G</given-names></name>, <name><surname>Epstein</surname><given-names>J</given-names></name>, <name><surname>Sesterhenn</surname><given-names>Ie</given-names></name>
<source>World Health Organization Classification of Tumors Pathology and Genetics of the Urinary Systemandmale Genital Organs</source>. <publisher-name>LARC Press</publisher-name>: <publisher-loc>Lyon</publisher-loc>, pp<fpage>12</fpage>&#x02013;<lpage>14</lpage>; <year>2004</year>.</mixed-citation></ref><ref id="pone.0118659.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Fuhrman</surname><given-names>SA</given-names></name>, <name><surname>Lasky</surname><given-names>LC</given-names></name>, <name><surname>Limas</surname><given-names>C</given-names></name>
<article-title>Prognostic significance of morphologic parameters in renal cell carcinoma</article-title>. <source>The American journal of surgical pathology</source>. <year>1982</year>;<volume>6</volume>(<issue>7</issue>):<fpage>655</fpage>&#x02013;<lpage>63</lpage>
<object-id pub-id-type="pmid">7180965</object-id>.<pub-id pub-id-type="pmid">7180965</pub-id></mixed-citation></ref><ref id="pone.0118659.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>F</given-names></name>, <name><surname>Grigorieva</surname><given-names>EV</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Senchenko</surname><given-names>VN</given-names></name>, <name><surname>Pavlova</surname><given-names>TV</given-names></name>, <name><surname>Anedchenko</surname><given-names>EA</given-names></name>, <etal>et al</etal>
<article-title>HYAL1 and HYAL2 inhibit tumour growth in vivo but not in vitro</article-title>. <source>PloS one</source>. <year>2008</year>;<volume>3</volume>(<issue>8</issue>):<fpage>e3031</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0003031">10.1371/journal.pone.0003031</ext-link></comment><object-id pub-id-type="pmid">18725949</object-id>; PubMed Central PMCID: PMC2516603.<pub-id pub-id-type="pmid">18725949</pub-id></mixed-citation></ref><ref id="pone.0118659.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Zeng</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>Q</given-names></name>, <name><surname>Zhao</surname><given-names>L</given-names></name>, <name><surname>Liu</surname><given-names>T</given-names></name>, <name><surname>Bjorkholm</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer</article-title>. <source>Molecular cancer</source>. <year>2010</year>;<volume>9</volume>:<fpage>132</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1476-4598-9-132">10.1186/1476-4598-9-132</ext-link></comment><object-id pub-id-type="pmid">20509972</object-id>; PubMed Central PMCID: PMC2887797.<pub-id pub-id-type="pmid">20509972</pub-id></mixed-citation></ref><ref id="pone.0118659.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Wolf</surname><given-names>D</given-names></name>, <name><surname>Wolf</surname><given-names>AM</given-names></name>, <name><surname>Rumpold</surname><given-names>H</given-names></name>, <name><surname>Fiegl</surname><given-names>H</given-names></name>, <name><surname>Zeimet</surname><given-names>AG</given-names></name>, <name><surname>Muller-Holzner</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer</article-title>. <source>Clinical cancer research: an official journal of the American Association for Cancer Research</source>. <year>2005</year>;<volume>11</volume>(<issue>23</issue>):<fpage>8326</fpage>&#x02013;<lpage>31</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1158/1078-0432.CCR-05-1244">10.1158/1078-0432.CCR-05-1244</ext-link></comment><object-id pub-id-type="pmid">16322292</object-id>.<pub-id pub-id-type="pmid">16322292</pub-id></mixed-citation></ref><ref id="pone.0118659.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>TC</given-names></name>, <name><surname>Sparks</surname><given-names>AB</given-names></name>, <name><surname>Rago</surname><given-names>C</given-names></name>, <name><surname>Hermeking</surname><given-names>H</given-names></name>, <name><surname>Zawel</surname><given-names>L</given-names></name>, <name><surname>da Costa</surname><given-names>LT</given-names></name>, <etal>et al</etal>
<article-title>Identification of c-MYC as a target of the APC pathway</article-title>. <source>Science</source>. <year>1998</year>;<volume>281</volume>(<issue>5382</issue>):<fpage>1509</fpage>&#x02013;<lpage>12</lpage>
<object-id pub-id-type="pmid">9727977</object-id>.<pub-id pub-id-type="pmid">9727977</pub-id></mixed-citation></ref><ref id="pone.0118659.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Tetsu</surname><given-names>O</given-names></name>, <name><surname>McCormick</surname><given-names>F</given-names></name>
<article-title>Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells</article-title>. <source>Nature</source>. <year>1999</year>;<volume>398</volume>(<issue>6726</issue>):<fpage>422</fpage>&#x02013;<lpage>6</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/18884">10.1038/18884</ext-link></comment><object-id pub-id-type="pmid">10201372</object-id>.<pub-id pub-id-type="pmid">10201372</pub-id></mixed-citation></ref><ref id="pone.0118659.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Rousseau</surname><given-names>B</given-names></name>, <name><surname>Menard</surname><given-names>L</given-names></name>, <name><surname>Haurie</surname><given-names>V</given-names></name>, <name><surname>Taras</surname><given-names>D</given-names></name>, <name><surname>Blanc</surname><given-names>JF</given-names></name>, <name><surname>Moreau-Gaudry</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma</article-title>. <source>Hepatology</source>. <year>2007</year>;<volume>46</volume>(<issue>4</issue>):<fpage>1108</fpage>&#x02013;<lpage>18</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/hep.21770">10.1002/hep.21770</ext-link></comment><object-id pub-id-type="pmid">17657734</object-id>.<pub-id pub-id-type="pmid">17657734</pub-id></mixed-citation></ref><ref id="pone.0118659.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>JH</given-names></name>, <name><surname>Lee</surname><given-names>JM</given-names></name>, <name><surname>Nam</surname><given-names>HJ</given-names></name>, <name><surname>Choi</surname><given-names>HJ</given-names></name>, <name><surname>Yang</surname><given-names>JW</given-names></name>, <name><surname>Lee</surname><given-names>JS</given-names></name>, <etal>et al</etal>
<article-title>SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source>. <year>2007</year>;<volume>104</volume>(<issue>52</issue>):<fpage>20793</fpage>&#x02013;<lpage>8</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0710343105">10.1073/pnas.0710343105</ext-link></comment><object-id pub-id-type="pmid">18087039</object-id>; PubMed Central PMCID: PMC2410081.<pub-id pub-id-type="pmid">18087039</pub-id></mixed-citation></ref><ref id="pone.0118659.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Dehan</surname><given-names>E</given-names></name>, <name><surname>Ben-Dor</surname><given-names>A</given-names></name>, <name><surname>Liao</surname><given-names>W</given-names></name>, <name><surname>Lipson</surname><given-names>D</given-names></name>, <name><surname>Frimer</surname><given-names>H</given-names></name>, <name><surname>Rienstein</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Chromosomal aberrations and gene expression profiles in non-small cell lung cancer</article-title>. <source>Lung cancer</source>. <year>2007</year>;<volume>56</volume>(<issue>2</issue>):<fpage>175</fpage>&#x02013;<lpage>84</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.lungcan.2006.12.010">10.1016/j.lungcan.2006.12.010</ext-link></comment><object-id pub-id-type="pmid">17258348</object-id>.<pub-id pub-id-type="pmid">17258348</pub-id></mixed-citation></ref><ref id="pone.0118659.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Sanchez-Carbayo</surname><given-names>M</given-names></name>, <name><surname>Socci</surname><given-names>ND</given-names></name>, <name><surname>Lozano</surname><given-names>J</given-names></name>, <name><surname>Saint</surname><given-names>F</given-names></name>, <name><surname>Cordon-Cardo</surname><given-names>C</given-names></name>
<article-title>Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2006</year>;<volume>24</volume>(<issue>5</issue>):<fpage>778</fpage>&#x02013;<lpage>89</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1200/JCO.2005.03.2375">10.1200/JCO.2005.03.2375</ext-link></comment><object-id pub-id-type="pmid">16432078</object-id>.<pub-id pub-id-type="pmid">16432078</pub-id></mixed-citation></ref><ref id="pone.0118659.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>JH</given-names></name>, <name><surname>Kim</surname><given-names>B</given-names></name>, <name><surname>Cai</surname><given-names>L</given-names></name>, <name><surname>Choi</surname><given-names>HJ</given-names></name>, <name><surname>Ohgi</surname><given-names>KA</given-names></name>, <name><surname>Tran</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes</article-title>. <source>Nature</source>. <year>2005</year>;<volume>434</volume>(<issue>7035</issue>):<fpage>921</fpage>&#x02013;<lpage>6</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature03452">10.1038/nature03452</ext-link></comment><object-id pub-id-type="pmid">15829968</object-id>.<pub-id pub-id-type="pmid">15829968</pub-id></mixed-citation></ref><ref id="pone.0118659.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Cram</surname><given-names>EJ</given-names></name>, <name><surname>Shang</surname><given-names>H</given-names></name>, <name><surname>Schwarzbauer</surname><given-names>JE</given-names></name>
<article-title>A systematic RNA interference screen reveals a cell migration gene network in C. elegans</article-title>. <source>Journal of cell science</source>. <year>2006</year>;<volume>119</volume>(<issue>Pt 23</issue>):<fpage>4811</fpage>&#x02013;<lpage>8</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1242/jcs.03274">10.1242/jcs.03274</ext-link></comment><object-id pub-id-type="pmid">17090602</object-id>.<pub-id pub-id-type="pmid">17090602</pub-id></mixed-citation></ref><ref id="pone.0118659.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Thiery</surname><given-names>JP</given-names></name>, <name><surname>Acloque</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>RY</given-names></name>, <name><surname>Nieto</surname><given-names>MA</given-names></name>
<article-title>Epithelial-mesenchymal transitions in development and disease</article-title>. <source>Cell</source>. <year>2009</year>;<volume>139</volume>(<issue>5</issue>):<fpage>871</fpage>&#x02013;<lpage>90</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2009.11.007">10.1016/j.cell.2009.11.007</ext-link></comment><object-id pub-id-type="pmid">19945376</object-id>.<pub-id pub-id-type="pmid">19945376</pub-id></mixed-citation></ref><ref id="pone.0118659.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Baum</surname><given-names>B</given-names></name>, <name><surname>Georgiou</surname><given-names>M</given-names></name>
<article-title>Dynamics of adherens junctions in epithelial establishment, maintenance, and remodeling</article-title>. <source>The Journal of cell biology</source>. <year>2011</year>;<volume>192</volume>(<issue>6</issue>):<fpage>907</fpage>&#x02013;<lpage>17</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1083/jcb.201009141">10.1083/jcb.201009141</ext-link></comment><object-id pub-id-type="pmid">21422226</object-id>; PubMed Central PMCID: PMC3063136.<pub-id pub-id-type="pmid">21422226</pub-id></mixed-citation></ref><ref id="pone.0118659.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Whitehead</surname><given-names>J</given-names></name>, <name><surname>Vignjevic</surname><given-names>D</given-names></name>, <name><surname>Futterer</surname><given-names>C</given-names></name>, <name><surname>Beaurepaire</surname><given-names>E</given-names></name>, <name><surname>Robine</surname><given-names>S</given-names></name>, <name><surname>Farge</surname><given-names>E</given-names></name>
<article-title>Mechanical factors activate beta-catenin-dependent oncogene expression in APC mouse colon</article-title>. <source>HFSP journal</source>. <year>2008</year>;<volume>2</volume>(<issue>5</issue>):<fpage>286</fpage>&#x02013;<lpage>94</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2976/1.2955566">10.2976/1.2955566</ext-link></comment><object-id pub-id-type="pmid">19404440</object-id>; PubMed Central PMCID: PMC2639941.<pub-id pub-id-type="pmid">19404440</pub-id></mixed-citation></ref></ref-list></back></article>